Evaluation of the predictive power of the CD147/EMMPRIN concentration in peripheral blood of patients with multiple myeloma

• Conditions: C90.0; Multiple myeloma

• Registration Number: DRKS00014659
• Lead Sponsor: Arbeitsgruppe Prof. Bassermann, Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der Technischen Universität München

Brief Summary

After enrolment of 25 patients with multiple myeloma, an interim analysis was performed. Unfortunately, the results didn’t show any evidence that the hypothesis of the scientific examination is true. The CD147 serum levels didn’t correlate with the response to therapy of the patients. Neither the initial absolute CD147 concentration nor the CD147 serum levels over time showed any significant correlation concerning response to therapy or disease progression. Serum levels of CD147 don’t seem to be a reliable biomarker for the prediction of therapy response in patients with multiple myeloma.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-04-24
• Study Completion: 2023-01-19
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting stopped after recruiting started
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Start/change of treatment of a patient with newly diagnosed/relapsed Multiple Myeloma with measurable paraprotein;
performance status ECOG Patients have to be treated routinely in the departement of internal medicine III of the university clinics of the technical university Munich.

Exclusion Criteria

non-secretory multiple myeloma;
HIV/ active Hep B/C infection;
other malignant disease

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Superiority of the analysis of the CD147 serum levels under treatment as an earlier predictive marker for the prediction of treatment response compared to the standard procedure of analysing changes in paraprotein levels.

Secondary Outcome Measures

Name	Time	Method
Can the CD147 serum level be used as an prognostic biomarker for the prediction of response (CR, VGPR, PR, ORR, etc.), progression free survival (PFS) and overal survival (OS)? Comparison of the CD147 serum levels of patients having multiple myeloma with healthy persons. Is it possible to define a threshold value for the prediction of a worse prognosis concerning response, progression free survival and overall survival?